| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
PTC Therapeutics (NASDAQ:PTCT) is currently in the final 18th phase of its Adhishthana cycle on the weekly chart, and the outlook remains bleak. Signals point to prolonged underperformance, with weakness likely to last through 2030. Here is how the structure unfolds under the Adhishthana framework.
In the Adhishthana framework, phases 14, 15, and 16 make up the Guna Triads. These determine whether a stock can achieve Nirvana in phase 18, the peak of the cycle. For Nirvana to materialize, the triads must show Satoguna, which represents a clean and sustained bullish structure.
Quoting from my book Adhishthana: The Principles That Govern Wealth, Time & Tragedy:
"A lack of noticeable Satoguna in any of the triads leads to no Nirvana in Phase 18."
For PTC Therapeutics, the triads played out from 2023 to 2024 without any signs of Satoguna. No phase delivered a clean bullish move, which rules out the possibility of a Nirvana rally in its current phase 18. Instead, the stock is set to remain in a slump until this phase ends in November 2026.
The longer-term outlook is no better. On the monthly chart, PTC Therapeutics is in phase 3, which will also end in November 2026. After that, the stock enters phase 4, which runs until May 2030. This phase is notorious for volatility, sharp rallies that quickly fade, and unstable trading behavior. It is widely considered a "no trade zone" for long-term investors.
The alignment of both weekly and monthly cycles paints a clear picture: PTC Therapeutics is headed nowhere fast. Extended slumps across multiple timeframes often reflect deeper structural or fundamental issues, and this case appears no different. Long-term investors should avoid the stock. Active traders may explore range-bound strategies such as credit spreads, but for most, PTCT is best left off the watchlist.
Benzinga Disclaimer: This article is from an unpaid external contributor. It does not represent Benzinga’s reporting and has not been edited for content or accuracy.
Posted In: PTCT
